Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3594149 | 0.77 | DRD2 (0.32) | PKMMAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL3594146 | 0.72 | MAPT (0.32) | PKMMAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL3594144 | 0.65 | DRD2 (0.37) | — | |
| SCHEMBL8472548 | 0.62 | CHRNB2 (0.43) | MAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL28319363 | 0.61 | TDP1 (0.42) | PKMMAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL2478764 | 0.61 | GAA (0.48) | SMN1; SMN2MEN1KMT2A | |
| SCHEMBL5446843 | 0.60 | GABRA1 (0.44) | MAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL256730 | 0.59 | UCHL1 (0.53) | MAPT | |
| SCHEMBL16706320 | 0.59 | GAA (0.38) | MAPTMEN1KMT2A | |
| SCHEMBL3589860 | 0.59 | SIGMAR1 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-2128157-A1 | HETEROCYCLIDENE-N-(ARYL)ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | CCNY, CCND3, NSD3 | PKM 3260/4885MAPT 4758/4885SMN1; SMN2 1047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.